ENDRA Life Sciences (NASDAQ:NDRA) Shares Down 7.7%

ENDRA Life Sciences Inc. (NASDAQ:NDRAGet Free Report)’s stock price fell 7.7% on Tuesday . The stock traded as low as $0.26 and last traded at $0.27. 1,583,340 shares changed hands during trading, an increase of 22% from the average session volume of 1,296,768 shares. The stock had previously closed at $0.29.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets dropped their price objective on ENDRA Life Sciences from $500.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, June 7th.

View Our Latest Stock Analysis on ENDRA Life Sciences

ENDRA Life Sciences Price Performance

The firm has a market capitalization of $17.68 million, a P/E ratio of -0.19 and a beta of 0.80. The stock has a fifty day simple moving average of $2.56 and a two-hundred day simple moving average of $15.51.

ENDRA Life Sciences (NASDAQ:NDRAGet Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01).

About ENDRA Life Sciences

(Get Free Report)

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.

Read More

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.